The disruption of protein−protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition

• Päätekijät: Michael A. Serwetnyk (Tekijä), Brian S.J. Blagg (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2021-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.
• Notes: 2211-3835; 10.1016/j.apsb.2020.11.015
• Keywords: Hsp90; Protein−protein interactions; Disruptors; Natural products; Small molecules; Peptidomimetics; Therapeutics. Pharmacology; RM1-950
• Source: Acta Pharmaceutica Sinica B, Vol 11, Iss 6, Pp 1446-1468 (2021)

The 90-kiloDalton (kD) heat shock protein (Hsp90) is a ubiquitous, ATP-dependent molecular chaperone whose primary function is to ensure the proper folding of several hundred client protein substrates. Because many of these clients are overexpressed or become mutated during cancer progression, Hsp90 inhibition has been pursued as a potential strategy for cancer as one can target multiple oncoproteins and signaling pathways simultaneously. The first discovered Hsp90 inhibitors, geldanamycin and radicicol, function by competitively binding to Hsp90's N-terminal binding site and inhibiting its ATPase activity. However, most of these N-terminal inhibitors exhibited detrimental activities during clinical evaluation due to induction of the pro-survival heat shock response as well as poor selectivity amongst the four isoforms. Consequently, alternative approaches to Hsp90 inhibition have been pursued and include C-terminal inhibition, isoform-selective inhibition, and the disruption of Hsp90 protein−protein interactions. Since the Hsp90 protein folding cycle requires the assembly of Hsp90 into a large heteroprotein complex, along with various co-chaperones and immunophilins, the development of small molecules that prevent assembly of the complex offers an alternative method of Hsp90 inhibition.